http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102313262-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2017-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102313262-B1 |
| titleOfInvention | Treatment of advanced HER2-expressing cancer |
| abstract | A method of treating a patient with HER2-positive, HER2-amplified and/or HER2-mutated advanced cancer by administration of Pertuzumab and Trastuzumab is disclosed. In one aspect, the cancer is an advanced HER2-positive, HER2-amplified and/or HER2-mutated colorectal, biliary tract, bladder, urothelium, salivary gland, lung, pancreas, ovarian, prostate or skin cancer. In another aspect, the cancer is HER2-positive, HER2-amplified and/or HER2-mutated colorectal, biliary tract, bladder, urothelium, salivary gland, lung, pancreas, ovary, refractory to one or more other treatment regimens; prostate or skin cancer. |
| priorityDate | 2016-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1042.